19300 Germantown Road
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as the "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer. The company employs more than 3,100 people in over 30 locations worldwide. QIAGEN’s North American headquarters is in Germantown, Maryland and its global headquarters is located in Hilden, Germany.
Further information about QIAGEN can be found at http://www.qiagen.com/.
95 articles with QIAGEN
SOPHiA GENETICS and QIAGEN Forge Partnership to Combine Strengths in Next-generation Sequencing
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced a new partnership with QIAGEN N.V. (NYSE: QGEN) that will pair QIAseq reagent technology with the SOPHiA DDM™ platform to enhance tumor analysis through next-generation sequencing (NGS).
QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new QIAseq Platform Partnership program and the first partnership with medical data-analysis provider SOPHiA GENETICSTM (Nasdaq: SOPH) that will bring together its QIAseq reagent technology for next-generation sequencing (NGS) with the SOPHiA DDMTM digital analytics platform.
QIAGEN’s tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR framework
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the certification of QuantiFERON-TB Gold Plus (QFT-Plus) – the world’s leading tuberculosis (TB) blood test – under the European Union’s 2017/746 In Vitro Diagnostic Medical Devices Regulation (IVDR) which is replacing the 98/79/EC In Vitro Diagnostic Directive (IVDD).
QIAGEN Launches EZ2 Connect MDx Platform for Automated Sample Processing in Diagnostic Labs
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of EZ2 Connect MDx for use in diagnostic laboratories, making the IVD platform for automated sample processing available for widescale use 18 months after being made available for research.
QIAGEN and Helix Launch Exclusive Partnership to Advance Next-Generation Sequencing Companion Diagnostics in Hereditary Diseases
QIAGEN announced an exclusive strategic partnership with California-based population genomics leader Helix to advance companion diagnostics for hereditary diseases.
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer
QIAGEN has announced the U.S. Food and Drug Administration approval of its therascreen® KRAS RGQ PCR kit as a companion diagnostic test to Mirati Therapeutic’s drug KRAZATI® for non-small cell lung cancer.
QIAGEN launches monkeypox test for NeuMoDx platform to fight global outbreak by boosting research and surveillance
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the monkeypox (MPXV) test for its NeuMoDx automated PCR platform to strengthen surveillance and research into the current outbreak in non-endemic regions that has infected tens of thousands of people all over the world since first being identified in May 2022.
QIAGEN Adds New Assays With CE-IVD Certification for NeuMoDx Integrated PCR System
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ transplant-associated viruses.
There's a new collaboration in the Parkinson's disease development space, Cardiff Oncology kicks off a mid-phase study in colorectal cancer and Ocugen published a new review of COVAXIN.
QIAGEN and Neuron23 Partner to Develop Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) and Neuron23 Inc. today announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson’s disease.
Neuron23 and QIAGEN Announce Collaboration to Develop the First Next-Generation Sequencing Companion Diagnostic for Novel Parkinson's Disease Drug
Neuron23™ Inc. and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to develop a companion diagnostic for Neuron23's LRRK2 inhibitor for Parkinson's disease.
QIAGEN Issues 2021 Sustainability Report
Greenhouse gas emissions intensity lowered by 16% and plastic footprint down 9.6% vs. 2020 Commitment to ambitious climate goals: Net-zero by 2050, Scope 1 and 2 emissions down 42% by 2030 Widening access to healthcare in high-burden, low-resource countries.
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service
QIAGEN announced a series of enhancements for its QIAcuity series of digital PCR instruments designed to drive greater use among customers, particularly those involved in the biopharma industry: New solutions are now available with ten new QIAcuity Cell and Gene Therapy dPCR Assays for use in adeno-associated virus titer quantification and three new QIAcuity Residual DNA Quantification Kits for checking carryover of host cell DNA.
QIAGEN beats outlook for Q2 2022 and raises full-year 2022 outlook
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the second quarter of 2022 and increased the outlook for full-year 2022.
QIAGEN’s Clinical Decision Support Platform QCI Surpasses Three Million NGS Patient Test Cases
QIAGEN Clinical Insights platform growing at over 35% annually, or 700,000 additional cases, and recently breaking through three million cases analyzed and reported.
The changes are unlikely to help people in developing countries but could reduce innovation among biopharma companies and ultimately do more harm than good.
ATCC Announces Expansion of its Bioinformatics Data Platform with QIAGEN
ATCC, the world’s premier biological materials management and standards organization, announced that it has entered into an agreement with QIAGEN, a recognized leader in bioinformatics solutions, to provide them with sequencing data from its collection of cell lines, and animal and human biological materials.
Singular Genomics Partners with QIAGEN to Enable QIAseq Kits for the G4 Sequencing Platform
Singular Genomics Systems, Inc. today announced a partnership with QIAGEN to validate its QIAseq kits, a product line for both DNA and RNA sample prep, with the G4 sequencing platform.
Element Biosciences Partners with QIAGEN to Validate a Selection of QIAseq Targeted Library Construction Chemistries on Element’s AVITI™ System
Element Biosciences, Inc. today announced a partnership with QIAGEN to validate its leading NGS library prep and target enrichment offerings on the AVITI System.
QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the fourth quarter and full-year 2021.